

FISCAL YEAR **2018**

\$1,354,372 Funding for AR Activities

Fiscal Year 2018

FUNDING TO STATE HEALTH DEPARTMENTS



RAPID DETECTION AND RESPONSE to novel or high-concern drug-resistant germs is critical to contain the spread of these infections.

With 2017 funding, New Jersey responded to more than 150 cases of *Candida auris* (an emerging, drug-resistant fungus) and helped healthcare facilities implement control measures to prevent spread of this multidrug-resistant yeast to other facilities and states.



HAI/AR PREVENTION works best when public health and healthcare facilities partner together to implement targeted, coordinated strategies to stop infections and improve antibiotic use.

With 2017 funding, New Jersey improved the ability of facilities in the state to quickly involve infection control professionals during drug diversion incidents through establishment of a multi-facility coalition with more than 40 healthcare professionals.



FOOD SAFETY projects protect communities by rapidly identifying drug-resistant foodborne bacteria to stop and solve outbreaks and improve prevention.

In Fiscal Year 2019, New Jersey will ramp up testing to include whole genome sequencing of all *Listeria*, *Salmonella*, *Campylobacter*, and *E. coli* isolates and simultaneously monitor these isolates for resistance genes. States upload the sequence data into PulseNet for nationwide monitoring of outbreaks and trends. When outbreaks are detected, local CDC-supported epidemiologists investigate the cases to stop spread.



FUNGAL DISEASE projects improve our ability to track antifungal resistance and stop it from spreading.

With funding for fungal disease surveillance, New Jersey increased their ability to identify fungal diseases, monitor for new and emerging resistance, and implement strategies to prevent its spread in high-risk areas. Improving detection for fungal diseases, like *Candida auris*, means patients receive appropriate treatment while reducing unnecessary antibiotic use.



GONORRHEA RAPID DETECTION & RESPONSE works with state and local epidemiology and laboratory partners to test for and quickly respond to resistant gonorrhea to stop its spread in high-risk communities.

To help inform national treatment guidelines for gonorrhea, New Jersey participates in the Gonococcal Isolate Surveillance Project (GISP), testing how well antibiotics work on laboratory samples from sentinel STD clinics, which are often the first to detect the threat.

Page 1 of 2 This data represents CDC's largest funding categories for AR. It shows extramural funding that supports AR activities from multiple funding lines.

AR: antibiotic resistance HAI: healthcare-associated infection

CDC provides critical support in the U.S. and abroad to protect people from antibiotic resistance.



U.S. Department of Health and Human Services Centers for Disease Control and Prevention

www.cdc.gov/ARinvestments

AR Solutions in Action

CDC's Investments to Combat Antibiotic Resistance Threats

NEW JERSEY AR Investments (cont.)

FUNDING TO UNIVERSITIES & HEALTHCARE PARTNERS



PRINCETON UNIVERSITY: Discovering & Implementing What Works

Researchers are assisting CDC with global partnerships and communications for best practices in combating antibiotic resistance and improving infection control and antibiotic use.



PRINCETON UNIVERSITY: Global Expertise & Capacity Enhancements

CDC's global work to combat AR prevents the importation of AR threats into the United States. Experts are working with CDC's International Infection Control Team on their global efforts to combat AR and improve antibiotic use.

Page 2 of 2 This data represents CDC's largest funding categories for AR. It shows extramural funding that supports AR activities from multiple funding lines.

AR: antibiotic resistance HAI: healthcare-associated infection

CDC provides critical support in the U.S. and abroad to protect people from antibiotic resistance.

www.cdc.gov/ARinvestments



U.S. Department of Health and Human Services Centers for Disease Control and Prevention